

Section 1 General principles

1 What is pharmacology? 1

- Overview 1
- What is a drug? 1
- Origins and antecedents 1
- Pharmacology in the 20th and 21st centuries 2
 - Alternative therapeutic principles 2
 - The emergence of biotechnology 3
 - Pharmacology today 4

2 How drugs act: general principles 6

- Overview 6
- Introduction 6
- Protein targets for drug binding 6
 - Drug receptors 6
 - Drug specificity 7
 - Receptor classification 8
 - Drug-receptor interactions 8
 - Competitive antagonism 10
 - Partial agonists and the concept of efficacy 11
 - Partial agonists as antagonists 13
 - Other forms of drug antagonism 16
- Desensitisation and tolerance 18
 - Change in receptors 18
 - Translocation of receptors 19
 - Exhaustion of mediators 19
 - Altered drug metabolism 19
 - Physiological adaptation 19
- Quantitative aspects of drug-receptor interactions 19
 - The binding reaction 19
 - Binding when more than one drug is present 20
- The nature of drug effects 21

3 How drugs act: molecular aspects 23

- Overview 23
- Protein targets for drug action 23
 - Receptors 23
 - Ion channels 23
 - Enzymes 24
 - Transporters 24
- Receptor proteins 25
 - Cloning of receptors 25
 - Types of receptor 25
 - Molecular structure of receptors 26
 - Type 1: Ligand-gated ion channels 27
 - Type 2: G protein-coupled receptors 29
 - Type 3: Kinase-linked and related receptors 40
 - Type 4: Nuclear receptors 44
- Ion channels as drug targets 46
 - Ion selectivity 47
 - Gating 47

- Molecular architecture of ion channels 48
- Pharmacology of ion channels 49
- Control of receptor expression 49
- Receptors and disease 49

4 How drugs act: cellular aspects – excitation, contraction and secretion 52

- Overview 52
- Regulation of intracellular calcium 52
 - Calcium entry mechanisms 52
 - Calcium extrusion mechanisms 55
 - Calcium release mechanisms 55
 - Calmodulin 56
- Excitation 56
 - The 'resting' cell 57
 - Electrical and ionic events underlying the action potential 57
 - Channel function 58
- Muscle contraction 61
 - Skeletal muscle 62
 - Cardiac muscle 64
 - Smooth muscle 64
- Release of chemical mediators 64
 - Exocytosis 65
 - Non-vesicular release mechanisms 66
- Epithelial ion transport 67

5 How drugs act: biopharmaceuticals and gene therapy 69

- Overview 69
- Introduction 69
- Protein and oligonucleotide biopharmaceuticals 69
- Proteins and polypeptides 70
 - Monoclonal antibodies 71
- Oligonucleotides 72
 - Pharmacology of protein and oligonucleotide pharmaceuticals 73
- Gene therapy 74
 - Gene delivery 75
 - Controlling gene expression 77
- Safety and societal issues 77
- Therapeutic applications 77
- Concluding remarks 79

6 Cell proliferation, apoptosis, repair and regeneration 82

- Overview 82
- Cell proliferation 82
 - The cell cycle 82
 - Interactions between cells, growth factors and the extracellular matrix 85
- Angiogenesis 86
- Apoptosis and cell removal 86
 - Morphological changes in apoptosis 87
 - The major players in apoptosis 87

CONTENTS

- Pathways to apoptosis 88
- Pathophysiological implications 89**
 - Repair and healing 89
 - Hyperplasia 89
 - The growth, invasion and metastasis of tumours 89
 - Stem cells and regeneration 90
- Therapeutic prospects 90**
 - Apoptotic mechanisms 90
 - Angiogenesis and metalloproteinases 91
 - Cell cycle regulation 91

7 Cellular mechanisms: host defence 93

- Overview 93**
- Introduction 93**
- The innate immune response 93**
 - Pattern recognition 93
- The adaptive immune response 98**
 - The induction phase 99
 - The effector phase 100
- Systemic responses in inflammation 103**
 - The role of the nervous system in inflammation 103
 - Unwanted inflammatory and immune responses 103
 - The outcome of the inflammatory response 104

8 Method and measurement in pharmacology 106

- Overview 106**
- Bioassay 106**
 - Biological test systems 106
 - General principles of bioassay 107
- Animal models of disease 110**
 - Genetic and transgenic animal models 110
- Pharmacological studies in humans 111**
- Clinical trials 111**
 - Avoidance of bias 112
 - The size of the sample 113
 - Clinical outcome measures 114
 - Placebos 114
 - Meta-analysis 114
 - Balancing benefit and risk 114

9 Absorption and distribution of drugs 117

- Overview 117**
- Introduction 117**
- Physical processes underlying drug disposition 117**
 - The movement of drug molecules across cell barriers 117
 - Binding of drugs to plasma proteins 121
 - Partition into body fat and other tissues 124
- Drug absorption and routes of administration 124**
 - Oral administration 124
 - Oromucosal (sublingual or buccal) administration 126
 - Rectal administration 127
 - Application to epithelial surfaces 127
- Distribution of drugs in the body 128**
 - Body fluid compartments 128

- Volume of distribution 129
- Special drug delivery systems 131

10 Drug metabolism and elimination 133

- Overview 133**
- Introduction 133**
 - Drug metabolism 133
 - Phase 1 reactions 133
 - Phase 2 reactions 135
 - Stereoselectivity 135
 - Inhibition of P450 136
 - Induction of microsomal enzymes 136
 - Presystemic ('first-pass') metabolism 136
 - Pharmacologically active drug metabolites 137
 - Drug interactions due to enzyme induction or inhibition 137
- Drug and metabolite excretion 139**
 - Biliary excretion and enterohepatic circulation 139
 - Renal excretion of drugs and metabolites 139
 - Drug interactions due to altered drug excretion 140

11 Pharmacokinetics 143

- Overview 143**
- Introduction: definition and uses of pharmacokinetics 143**
 - Uses of pharmacokinetics 144
 - Scope of this chapter 144
- Drug elimination expressed as clearance 144**
- Single-compartment model 145**
 - Effect of repeated dosing 146
 - Effect of variation in rate of absorption 146
- More complicated kinetic models 147**
 - Two-compartment model 148
 - Saturation kinetics 149
- Population pharmacokinetics 149**
- Limitations of pharmacokinetics 150**

12 Individual variation, pharmacogenomics and personalised medicine 152

- Overview 152**
- Introduction 152**
- Epidemiological factors and inter-individual variation of drug response 153**
 - Ethnicity 153
 - Age 153
 - Pregnancy 155
 - Disease 155
 - Drug interactions 155
- Genetic variation in drug responsiveness 156**
 - Single-gene pharmacokinetic disorders 157
- Therapeutic drugs and clinically available pharmacogenomic tests 159**
 - HLA gene tests 159
 - Drug metabolism-related gene tests 160
 - Drug target-related gene tests ('companion diagnostics') 161
 - Combined (metabolism and target) gene tests 161
- Conclusions 161**

Section 2 Chemical mediators

13 Chemical mediators and the autonomic nervous system 163

Overview 163

Historical aspects 163

The autonomic nervous system 164

Basic anatomy and physiology 164

Transmitters in the autonomic nervous system 165

Some general principles of chemical transmission 167

Presynaptic modulation 167

Postsynaptic modulation 169

Transmitters other than acetylcholine and noradrenaline 170

Co-transmission 170

Termination of transmitter action 170

Denervation supersensitivity 171

Basic steps in neurochemical transmission: sites of drug action 173

14 Cholinergic transmission 175

Overview 175

Muscarinic and nicotinic actions of acetylcholine 175

Acetylcholine receptors 175

Nicotinic receptors 175

Muscarinic receptors 177

Physiology of cholinergic transmission 178

Acetylcholine synthesis and release 178

Electrical events in transmission at fast cholinergic synapses 180

Effects of drugs on cholinergic transmission 181

Drugs affecting muscarinic receptors 181

Drugs affecting autonomic ganglia 185

Drugs that act presynaptically 190

Drugs that enhance cholinergic transmission 192

Other drugs that enhance cholinergic transmission 196

15 Noradrenergic transmission 197

Overview 197

Catecholamines 197

Classification of adrenoceptors 197

Physiology of noradrenergic transmission 198

The noradrenergic neuron 198

Uptake and degradation of catecholamines 201

Drugs acting on noradrenergic transmission 202

Drugs acting on adrenoceptors 202

Drugs that affect noradrenergic neurons 213

16 5-Hydroxytryptamine and the pharmacology of migraine 217

Overview 217

5-Hydroxytryptamine 217

Distribution, biosynthesis and degradation 217

Pharmacological effects 221

Drugs acting at 5-HT receptors 221

Migraine and other clinical conditions in which 5-HT plays a role 223

Migraine and antimigraine drugs 223

Antimigraine drugs 224

Carcinoid syndrome 224

Pulmonary hypertension 225

17 Purines 228

Overview 228

Introduction 228

Purinergic receptors 228

Adenosine as a mediator 228

Adenosine and the cardiovascular system 230

Adenosine in asthma 231

Adenosine in inflammation 231

Adenosine in the CNS 231

ADP as a mediator 231

ADP and platelets 231

ATP as a mediator 231

ATP as a neurotransmitter 231

ATP in nociception 232

ATP in inflammation 232

Future prospects 232

18 Local hormones 1: histamine and the biologically active lipids 233

Overview 233

Introduction 233

What is a 'mediator'? 233

Histamine 233

Synthesis and storage of histamine 234

Histamine release 234

Histamine receptors 234

Actions 234

Eicosanoids 235

General remarks 235

Structure and biosynthesis 235

Prostanoids 235

Leukotrienes 240

Leukotriene receptors 240

Leukotriene actions 241

Other important fatty acid derivatives 241

Platelet-activating factor 242

Biosynthesis 242

Actions and role in inflammation 242

Concluding remarks 242

19 Local hormones 2: peptides and proteins 244

Overview 244

Introduction 244

General principles of protein and peptide pharmacology 244

Structure 244

Types of protein and peptide mediator 244

Biosynthesis and regulation of peptides 245

Peptide precursors 246

Diversity within peptide families 246

Peptide trafficking and secretion 246

Bradykinin 247

Source and formation of bradykinin 247

Metabolism and inactivation of bradykinin 247

CONTENTS

- Bradykinin receptors 247
- Actions and role in inflammation 247
- Neuropeptides 248**
- Cytokines 248**
- Interleukins and related compounds 249
- Chemokines 249
- Interferons 249
- The 'cytokine storm' 251
- Proteins and peptides that down-regulate inflammation 251**
- Concluding remarks 251

20 Cannabinoids 253

- Overview 253
- Plant-derived cannabinoids and their pharmacological effects 253
- Pharmacological effects 253
- Pharmacokinetic aspects 253
- Adverse effects 253
- Tolerance and dependence 254
- Cannabinoid receptors 254**
- Endocannabinoids 255**
- Biosynthesis of endocannabinoids 255
- Termination of the endocannabinoid signal 256
- Physiological mechanisms 257
- Pathological involvement 257
- Synthetic cannabinoids 258**
- Clinical applications 258

21 Nitric oxide and related mediators 260

- Overview 260
- Introduction 260
- Biosynthesis of nitric oxide and its control 260
- Degradation and carriage of nitric oxide 262
- Effects of nitric oxide 263
- Biochemical and cellular aspects 263
- Vascular effects 264
- Neuronal effects 264
- Host defence 264
- Therapeutic aspects 265**
- Nitric oxide 265
- Nitric oxide donors/precursors 265
- Inhibition of nitric oxide synthesis 265
- Nitric oxide replacement or potentiation 266
- Clinical conditions in which nitric oxide may play a part 266**
- Related mediators 267

Section 3 Drugs affecting major organ systems

22 The heart 271

- Overview 271
- Introduction 271
- Physiology of cardiac function 271
- Cardiac rate and rhythm 271
- Cardiac contraction 274
- Myocardial oxygen consumption and coronary blood flow 275

- Autonomic control of the heart 276**
- Sympathetic system 276
- Parasympathetic system 277
- Cardiac natriuretic peptides 278**
- Ischaemic heart disease 278**
- Angina 278
- Myocardial infarction 279
- Drugs that affect cardiac function 279**
- Antiarrhythmic drugs 279
- Drugs that increase myocardial contraction 283
- Anti-anginal drugs 284

23 The vascular system 290

- Overview 290
- Introduction 290
- Vascular structure and function 290
- Control of vascular smooth muscle tone 291
- The vascular endothelium 291
- The renin-angiotensin system 295
- Vasoactive drugs 296**
- Vasoconstrictor drugs 296
- Vasodilator drugs 297
- Clinical uses of vasoactive drugs 301**
- Systemic hypertension 301
- Heart failure 304
- Vasodilatory shock and hypotensive states 306
- Peripheral vascular disease 307
- Raynaud's disease 307
- Pulmonary hypertension 307

24 Atherosclerosis and lipoprotein metabolism 310

- Overview 310
- Introduction 310
- Atherogenesis 310
- Lipoprotein transport 311
- Dyslipidaemia 312
- Prevention of atheromatous disease 313**
- Lipid-lowering drugs 314**
- Statins: HMG-CoA reductase inhibitors 314
- Proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors 315
- Fibrates 315
- Drugs that inhibit cholesterol absorption 316
- Nicotinic acid 316
- Fish oil derivatives 316
- Mipomersen 317
- Lomitapide 317

25 Haemostasis and thrombosis 319

- Overview 319
- Introduction 319
- Blood coagulation 319
- Coagulation cascade 319
- Vascular endothelium in haemostasis and thrombosis 321
- Drugs that act on the coagulation cascade 322**
- Coagulation defects 322
- Thrombosis 323
- Platelet adhesion and activation 327**
- Antiplatelet drugs 329
- Fibrinolysis (thrombolysis) 330**
- Fibrinolytic drugs 331

26 Haematopoietic system and treatment of anaemia 334

Overview 334

Introduction 334

The haematopoietic system 334

Types of anaemia 334

Haematinic agents 335

Iron 335

Folic acid and vitamin B₁₂ 337

Haematopoietic growth factors 338

Haemolytic anaemia 341

Drugs used to treat haemolytic anaemias 341

27 Anti-inflammatory and immunosuppressant drugs 343

Overview 343

Introduction 343

Cyclo-oxygenase inhibitors 343

Mechanism of action 344

Pharmacological actions 345

Therapeutic actions 346

Some important NSAIDs and coxibs 348

Antirheumatoid drugs 351

Anticytokine drugs and other biopharmaceuticals 355

Drugs used in gout 356

Antagonists of histamine 358

Possible future developments in antiinflammatory therapy 359

28 Skin 362

Overview 362

Introduction 362

Structure of skin 362

Common diseases of the skin 364

Acne 364

Rosacea 365

Baldness and hirsutism 365

Eczema 365

Pruritus 365

Urticaria 365

Psoriasis 366

Warts 366

Other infections 366

Drugs acting on skin 366

Formulation 366

Principal drugs used in skin disorders 366

Antimicrobial agents 366

Glucocorticoids and other anti-inflammatory agents 367

Drugs used to control hair growth 367

Retinoids 368

Vitamin D analogues 369

Agents acting by other mechanisms 369

Concluding remarks 369

29 Respiratory system 371

Overview 371

The physiology of respiration 371

Control of breathing 371

Regulation of musculature, blood vessels and glands of the airways 371

Pulmonary disease and its treatment 372

Bronchial asthma 372

Drugs used to treat and prevent asthma 375

Severe acute asthma (status asthmaticus) 379

Allergic emergencies 379

Chronic obstructive pulmonary disease 379

Idiopathic pulmonary fibrosis 380

Surfactants 380

Cough 380

30 The kidney and urinary system 382

Overview 382

Introduction 382

Outline of renal function 382

The structure and function of the nephron 382

Tubular function 384

Acid-base balance 387

Potassium balance 388

Excretion of organic molecules 388

Natriuretic peptides 388

Prostaglandins and renal function 388

Drugs acting on the kidney 388

Diuretics 388

Drugs that alter the pH of the urine 392

Drugs that alter the excretion of organic molecules 392

Drugs used in renal failure 393

Hyperphosphataemia 393

Hyperkalaemia 393

Drugs used in urinary tract disorders 393

31 The gastrointestinal tract 395

Overview 395

The innervation and hormones of the gastrointestinal tract 395

Neuronal control 395

Hormonal control 395

Gastric secretion 395

The regulation of acid secretion by parietal cells 395

The coordination of factors regulating acid secretion 396

Drugs used to inhibit or neutralise gastric acid secretion 397

Treatment of *Helicobacter pylori* infection 399

Drugs that protect the mucosa 400

Vomiting 400

The reflex mechanism of vomiting 400

Antiemetic drugs 401

The motility of the GI tract 403

Purgatives 404

Drugs that increase gastrointestinal motility 404

Antidiarrhoeal agents 405

Drugs for chronic bowel disease 406

Drugs affecting the biliary system 406

Future directions 407

32 The control of blood glucose and drug treatment of diabetes mellitus 408

Overview 408

Introduction 408

Control of blood glucose 408

CONTENTS

- Pancreatic islet hormones **409**
 - Insulin 410
 - Glucagon 412
 - Somatostatin 413
 - Amylin (islet amyloid polypeptide) 413
 - Incretins 413
- Diabetes mellitus **413**
 - Drugs used in the treatment of diabetes 414
 - Treatment of diabetes mellitus 419

33 Obesity 422

- Overview **422**
- Introduction **422**
 - Definition of obesity 422
- Obesity as a health problem **422**
- Homeostatic mechanisms controlling energy balance **423**
 - The role of gut and other hormones in body weight regulation 423
 - Neurological circuits that control body weight and eating behaviour 423
- The pathophysiology of human obesity **426**
 - Food intake and obesity 426
 - Physical exercise and obesity 427
 - Obesity as a disorder of the homeostatic control of energy balance 427
 - Genetic factors and obesity 427
- Pharmacological approaches to the problem of obesity **428**
 - Centrally acting appetite suppressants 429
 - Orlistat 429
- New approaches to obesity therapy **430**

34 The pituitary and the adrenal cortex 432

- Overview **432**
- The pituitary gland **432**
 - The anterior pituitary gland 432
 - Hypothalamic hormones 432
 - Anterior pituitary hormones 433
 - Posterior pituitary gland 437
- The adrenal cortex **438**
 - Glucocorticoids 440
 - Mineralocorticoids 444
- New directions in glucocorticoid therapy **445**

35 The thyroid 448

- Overview **448**
- Synthesis, storage and secretion of thyroid hormones **448**
 - Uptake of plasma iodide by the follicle cells 448
 - Oxidation of iodide and iodination of tyrosine residues 448
 - Secretion of thyroid hormone 448
- Regulation of thyroid function **448**
- Actions of the thyroid hormones **450**
 - Effects on metabolism 450
 - Effects on growth and development 451
 - Mechanism of action 451
- Transport and metabolism of thyroid hormones **451**
- Abnormalities of thyroid function **451**
 - Hyperthyroidism (thyrotoxicosis) 451
 - Simple, non-toxic goitre 452
 - Hypothyroidism 452

- Drugs used in diseases of the thyroid **452**
 - Hyperthyroidism 452
 - Hypothyroidism 453

36 The reproductive system 455

- Overview **455**
- Introduction **455**
- Endocrine control of reproduction **455**
 - Neurohormonal control of the female reproductive system 455
 - Neurohormonal control of the male reproductive system 457
 - Behavioural effects of sex hormones 458
- Drugs affecting reproductive function **458**
 - Oestrogens 458
 - Antioestrogens 459
 - Progestogens 459
 - Postmenopausal hormone replacement therapy (HRT) 460
 - Androgens 461
 - Anabolic steroids 461
 - Anti-androgens 462
 - Gonadotrophin-releasing hormone: agonists and antagonists 462
 - Gonadotrophins and analogues 463
- Drugs used for contraception **463**
 - Oral contraceptives 463
 - Other drug regimens used for contraception 464
- The uterus **465**
 - The motility of the uterus 465
 - Drugs that stimulate the uterus 465
 - Drugs that inhibit uterine contraction 466
- Erectile dysfunction **467**

37 Bone metabolism 470

- Overview **470**
- Introduction **470**
- Bone structure and composition **470**
- Bone remodelling **470**
 - The action of cells and cytokines 470
 - The turnover of bone minerals 472
 - Hormones involved in bone metabolism and remodelling 473
- Disorders of bone **474**
- Drugs used in bone disorders **475**
 - Bisphosphonates 475
 - Oestrogens and related compounds 476
 - Parathyroid hormone and teriparatide 476
 - Vitamin D preparations 477
 - Biopharmaceuticals 477
 - Calcitonin 477
 - Calcium salts 477
 - Calcimimetic compounds 478
- Potential new therapies **478**

Section 4 Nervous system

38 Chemical transmission and drug action in the central nervous system 480

- Overview **480**
- Introduction **480**

Chemical signalling in the nervous system **480**
Targets for drug action **482**
Drug action in the central nervous system **483**
Blood-brain barrier 483
The classification of psychotropic drugs **484**

39 Amino acid transmitters 486

Overview **486**
Excitatory amino acids **486**
Excitatory amino acids as CNS transmitters 486
Metabolism and release of excitatory amino acids 486
Glutamate **487**
Glutamate receptor subtypes 487
Synaptic plasticity and long-term potentiation 491
Drugs acting on glutamate receptors 491
 γ -Aminobutyric acid (GABA) **493**
Synthesis, storage and function 493
GABA receptors: structure and pharmacology 494
Drugs acting on GABA receptors 496
Glycine **497**
Concluding remarks **497**

40 Other transmitters and modulators 499

Overview **499**
Introduction **499**
Noradrenaline **499**
Noradrenergic pathways in the CNS 499
Functional aspects 500
Dopamine **500**
Dopaminergic pathways in the CNS 501
Dopamine receptors 502
Functional aspects 502
5-Hydroxytryptamine **504**
5-HT pathways in the CNS 504
5-HT receptors in the CNS 504
Functional aspects 505
Clinically used drugs 506
Acetylcholine **506**
Cholinergic pathways in the CNS 507
Acetylcholine receptors 507
Functional aspects 507
Purines **508**
Histamine **509**
Other CNS mediators **509**
Melatonin 509
Nitric oxide 509
Lipid mediators 510
A final message **512**

41 Neurodegenerative diseases 514

Overview **514**
Protein misfolding and aggregation in chronic neurodegenerative diseases **514**
Mechanisms of neuronal death **514**
Excitotoxicity 516
Apoptosis 516
Oxidative stress 516
Ischaemic brain damage **518**
Pathophysiology 518
Therapeutic approaches 519
Alzheimer's disease **519**
Pathogenesis of Alzheimer's disease 519

Therapeutic approaches 521
Parkinson's disease **522**
Features of Parkinson's disease 522
Pathogenesis of Parkinson's disease 523
Drug treatment of Parkinson's disease 524
Huntington's disease **527**
Amyotrophic lateral sclerosis **528**
Spinal muscular atrophy **528**
Multiple sclerosis **528**

42 General anaesthetic agents 531

Overview **531**
Introduction **531**
Mechanism of action of anaesthetic drugs **531**
Lipid solubility 531
Effects on ion channels 532
Effects on the nervous system 533
Effects on the cardiovascular and respiratory systems 533
Intravenous anaesthetic agents **534**
Propofol 534
Thiopental 534
Etomidate 535
Other intravenous agents 535
Inhalation anaesthetics **536**
Pharmacokinetic aspects 536
Individual inhalation anaesthetics **539**
Isoflurane, desflurane, sevoflurane, enflurane and halothane 539
Nitrous oxide 540
Balanced anaesthesia **540**

43 Analgesic drugs 542

Overview **542**
Neural mechanisms of pain **542**
Nociceptive afferent neurons 542
Modulation in the nociceptive pathway 543
Neuropathic pain **546**
Chemical signalling in the nociceptive pathway **546**
Analgesic drugs **548**
Opioid drugs 548
Paracetamol 559
Treatment of chronic pain 559
Other pain-relieving drugs 560
New approaches 560

44 Local anaesthetics and other drugs affecting sodium channels 563

Overview **563**
Local anaesthetics **563**
Chemical aspects 563
Mechanism of action 563
Pharmacokinetic aspects 566
New approaches 566
Other drugs that affect sodium channels **567**
Tetrodotoxin and saxitoxin 567
Agents that affect sodium-channel gating 568

45 Anxiolytic and hypnotic drugs 569

Overview **569**
The nature of anxiety and its treatment **569**
Measurement of anxiolytic activity **569**
Animal models of anxiety 569

CONTENTS

- Tests on humans 570
- Drugs used to treat anxiety 571
- Delayed anxiolytic effect of SSRIs and buspirone 572
 - Benzodiazepines and related drugs 572
 - Other potential anxiolytic drugs 576
- Drugs used to treat insomnia (hypnotic drugs) 577
 - Induction of sleep by benzodiazepines 578

46 Antiepileptic drugs 580

- Overview 580
- Introduction 580
- The nature of epilepsy 580
 - Types of epilepsy 580
 - Neural mechanisms and animal models of epilepsy 582
- Antiepileptic drugs 582
 - Carbamazepine 586
 - Phenytoin 586
 - Valproate 587
 - Ethosuximide 588
 - Phenobarbital 588
 - Benzodiazepines 588
 - Newer antiepileptic drugs 589
 - New drugs 590
 - Other uses of antiepileptic drugs 590
 - Antiepileptic drugs and pregnancy 590
- Muscle spasm and muscle relaxants 590

47 Antipsychotic drugs 592

- Overview 592
- Introduction 592
- The nature of schizophrenia 592
 - Aetiology and pathogenesis of schizophrenia 593
- Antipsychotic drugs 595
 - Classification of antipsychotic drugs 595
 - Clinical efficacy in treatment of schizophrenia 595
 - Other uses of antipsychotic drugs 598
 - Pharmacological properties 598
 - Unwanted effects 599
 - Pharmacokinetic aspects 601
- Future developments 601

48 Antidepressant drugs 603

- Overview 603
- The nature of depression 603
- Theories of depression 603
 - The monoamine theory 603
 - Negative affective bias 604
 - Neuroendocrine mechanisms 604
 - Trophic effects and neuroplasticity 605
- Antidepressant drugs 606
 - Types of antidepressant drug 606
 - Testing of antidepressant drugs 607
 - Mechanism of action of antidepressant drugs 611
 - Monoamine uptake inhibitors 611
 - Monoamine receptor antagonists 616
 - Monoamine oxidase inhibitors 616
 - Melatonin agonist 618
 - Ketamine 618
 - Other antidepressant approaches 618
- Clinical effectiveness of antidepressant treatments 618
- Future antidepressant drugs 619
- Brain stimulation therapies 619
- Drug treatment of bipolar disorder 620

- Lithium 620
- Antiepileptic drugs 621
- Second-generation antipsychotic drugs 621

49 Psychoactive drugs 623

- Overview 623
- Introduction 623
- Psychomotor stimulants 623
 - Amphetamines 623
 - Methylphenidate 625
 - Modafinil 626
 - Cocaine 626
 - MDMA 628
 - Cathinones 628
 - Methylxanthines 629
 - Nicotine 629
 - Pharmacological effects of nicotine 630
 - Pharmacokinetic aspects 631
 - Tolerance and dependence 631
 - Harmful effects of tobacco smoking 632
- Cognition-enhancing drugs 633
- Psychedelic drugs 634
 - LSD, psilocybin and mescaline 634
 - Other psychedelic drugs 635
- Ketamine and related drugs 635
- Depressants 635
 - Ethanol 636
 - Pharmacological effects of ethanol 636
 - Pharmacokinetic aspects 638
- Tolerance and dependence 640
- Synthetic cannabinoids 640

50 Drug abuse and dependence 642

- Overview 642
- Drug use and abuse 642
 - Drug administration 642
 - Drug harm 643
 - Drug dependence 643
 - Withdrawal 644
 - Tolerance 646
 - Pharmacological approaches to treating drug dependence 646

Section 5 Drugs used for the treatment of infections and cancer

51 Basic principles of antimicrobial chemotherapy 649

- Overview 649
- Background 649
- The molecular basis of chemotherapy 649
 - Bacteria 649
 - Biochemical reactions as potential targets 650
 - The formed structures of the cell as potential targets 654
- Resistance to antibacterial drugs 656
 - The spread of antibiotic resistance 656
 - Biochemical mechanisms of resistance to antibiotics 657
- Current status of antibiotic resistance in bacteria 659

52 Antibacterial drugs 661

Overview 661

Introduction 661

Antibacterial agents that interfere with folate synthesis or action 661

Sulfonamides 661

Trimethoprim 662

β -lactam antibiotics and other agents that interfere with bacterial wall or membrane synthesis 663

Penicillins 663

Cephalosporins and cephamycins 665

Other β -lactam antibiotics 665

Other antibiotics that inhibit bacterial cell wall peptidoglycan synthesis 665

Antimicrobial agents affecting bacterial protein synthesis 666

Tetracyclines 666

Chloramphenicol 667

Aminoglycosides 667

Macrolides 670

Oxazolidinones 670

Fusidic acid 671

Streptogramins 671

Clindamycin 671

Antimicrobial agents affecting topoisomerase 672

Quinolones 672

Miscellaneous antibacterial agents 672

Antimycobacterial agents 673

Drugs used to treat tuberculosis 673

Drugs used to treat leprosy 675

Possible new antibacterial drugs 675

53 Antiviral drugs 678

Overview 678

Background information about viruses 678

An outline of virus structure 678

Examples of pathogenic viruses 678

Virus function and life history 678

The host-virus interaction 679

Host defences against viruses 679

Viral ploys to circumvent host defences 680

HIV and AIDS 680

Induction of the disease 681

Progress of infection 681

Antiviral drugs 681

Reverse transcriptase inhibitors 684

Non-nucleoside reverse transcriptase inhibitors 684

Protease inhibitors 685

DNA polymerase inhibitors 685

Neuraminidase inhibitors and inhibitors of viral coat disassembly 685

Drugs acting through other mechanisms 686

Biopharmaceutical antiviral drugs 686

Other agents 686

Combination therapy for HIV 687

Prospects for new antiviral drugs 687

54 Antifungal drugs 690

Overview 690

Fungi and fungal infections 690

Drugs used to treat fungal infections 691

Antifungal antibiotics 691

Synthetic antifungal drugs 693

Future developments 694

55 Antiprotozoal drugs 696

Overview 696

Background 696

Host-parasite interactions 696

Malaria and antimalarial drugs 696

The life cycle of the malaria parasite 698

Antimalarial drugs 699

Potential new antimalarial drugs 705

Amoebiasis and amoebicidal drugs 705

Trypanosomiasis and trypanocidal drugs 706

Other protozoal infections and drugs used to treat them 707

Leishmaniasis 707

Trichomoniasis 707

Giardiasis 708

Toxoplasmosis 708

Pneumocystis 708

Future developments 708

56 Anthelmintic drugs 710

Overview 710

Helminth infections 710

Anthelmintic drugs 711

Resistance to anthelmintic drugs 713

Vaccines and other novel approaches 714

57 Anticancer drugs 716

Overview 716

Introduction 716

The pathogenesis of cancer 716

The genesis of a cancer cell 717

The special characteristics of cancer cells 717

General principles of cytotoxic anticancer drugs 719

Anticancer drugs 720

Alkylating agents and related compounds 722

Antimetabolites 723

Cytotoxic antibiotics 724

Plant derivatives 726

Hormones 726

Hormone antagonists 727

Monoclonal antibodies 727

Protein kinase inhibitors 728

Miscellaneous agents 729

Resistance to anticancer drugs 729

Combination therapies 730

Control of emesis and myelosuppression 730

Future developments 730

Section 6 Special topics

58 Harmful effects of drugs 733

Overview 733

Introduction 733

Classification of adverse drug reactions 733

Adverse effects related to the known action of the drug 733

CONTENTS

Adverse effects unrelated to the known pharmacological action of the drug 734

Drug toxicity 734

Toxicity testing 734

General mechanisms of toxin-induced cell damage and cell death 735

Mutagenesis and assessment of genotoxic potential 736

Immunological reactions to drugs 741

Immunological mechanisms 742

Clinical types of allergic response to drugs 742

59 Lifestyle and drugs in sport 744

Overview 744

What are lifestyle drugs? 744

Classification of lifestyle drugs 744

Drugs and sex 745

Drugs in sport 745

Anabolic steroids 746

Human growth hormone 748

Stimulant drugs 748

Conclusion 748

60 Drug discovery and development 750

Overview 750

The stages of a project 750

The drug discovery phase 750

Preclinical development 752

Clinical development 753

Biopharmaceuticals 753

Commercial aspects 754

Future prospects 754

A final word 755

Index 756

Self-assessment questions compiled by Dr. Christine Edmead, University of Bath, are available through <https://studentconsult.inkling.com>